Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma

NCT03168607 | Unknown Phase 2 DMC

• 1 other identifier: FOLFIRI-2
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

Currently, there is no standard second line treatment for patients with neuroendocrine carcinoma. Irinotecan monotherapy or combination regimen has shown promising in previous study. The study was designed to confirm thet FOLFIRI regimen can be used as a second-line regimen for patients with advanced or metastatic neuroendocrine carcinoma who have progressed after first-line chemotherapy with platinum based regimen.

Conditions

Neuroendocrine Carcinoma

Keywords

ORR; OS; PFS; safety

Outcome Measures

Primary Outcomes (1)

• Overall response rate (ORR)

  CT/MRI will be performed every 2 cycles of treatment for efficacy evaluation by RECIST 1.1

  From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Secondary Outcomes (3)

• Progression-free survival

  baseline, every 8 weeks up to 1 year after last patient first treatment

• Overall survival

  baseline, every 8 weeks up to 1 year after last patient first treatment

• Incidence of Treatment-related Adverse Events （Safety and Tolerability）

  From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Study Arms (1)

FOLFIRI

EXPERIMENTAL

Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W

Drug: FOLFIRI Protocol

Interventions

FOLFIRI Protocol DRUG

Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W

FOLFIRI

Eligibility Criteria

• Age: 18 Years+
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• sign written informed consent form
• age ≥ 18 years
• pathologically confirmed poorly-differentiated neuroendocrine carcinoma, G3(Ki67\>20%);
• No prior antitumor treatment with irinotecan, progress after first line chemotherapy with platinum-based regimen. For recurrent patients after radical surgery, platinum-based adjuvant chemotherapy should beyond 6 months prior to randomization;
• At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan \>=20mm, spiral CT scan \>=10mm, no prior radiation to measurable lesions);
• Screening laboratory values must meet the following criteria (within past 7 days): hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ μL; platelets ≥ 100 x 10\^3/ μL; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1╳ULN;
• KPS ≥ 70;
• Predicted survival \>=3 months;
• Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women;
• Sexually active males or females willing to practice contraception during the study until 30 days after end of study.

You may not qualify if:

• Hypersensitivity to IRI,5-HT3 receptor antagonists;
• Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;
• Received surgery within past 4 weeks, or have not recovered from surgery;
• Severe diarrhea;
• Concurrent severe infection；
• Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including severe liver disease (active hepatitis, cirrhosis), uncontrolled diabetes or hypertension, or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm);
• Prior long term steroid therapy (excluding short term steroid treatment which is completed prior to \> 2 weeks of study enrollment)；
• Meningeal carcinomatosis;
• Patients with central nervous system(CNS) disorder or peripheral nervous system disorder or psychiatric disease；
• Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency；
• Pregnant or nursing, or sexually active males or females refuse to practice contraception during the study until 30 days after end of study;
• History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible；
• Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons；
• Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.

Sponsors & Collaborators

• Peking University: lead

Study Sites (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Neuroendocrine

Interventions

IFL protocol

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Central Study Contacts

Lin Shen

CONTACT

86-10-88196561; linshenpku@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, Professor, Chief of Department of GI Oncology, Peking University Cancer Hospital

Study Record Dates

• First Submitted: May 10, 2017
• First Posted: May 30, 2017
• Study Start: May 2, 2017
• Primary Completion: May 2, 2019
• Study Completion: May 2, 2020
• Last Updated: June 1, 2017

Record last verified: 2017-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)